Vortioxetine

證據等級: L5

預測適應症: 5 個

Vortioxetine: From Major Depressive Disorder to Neurotic Disorder

One-Sentence Summary

Vortioxetine is a multimodal serotonergic antidepressant originally developed and used for Major Depressive Disorder (MDD). The TxGNN model's top-ranked prediction suggests possible efficacy in Neurotic Disorder — a broad, heterogeneous ICD-9 category covering anxiety, dissociative, and somatoform conditions — but this is currently supported by only 1 indirect clinical trial and 1 review-level publication, making the evidence base thin relative to the model's high confidence score.

Quick Overview

Item	Content
Original Indication	Major Depressive Disorder (MDD) — per literature evidence; no Finland license record available (drug not marketed)
Predicted New Indication	Neurotic Disorder
TxGNN Prediction Score	99.24%
Evidence Level	L4
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for vortioxetine is flagged as a data gap in this evidence pack (DG002, High severity). Based on information available in the associated literature (e.g., PMID 25016186, PMID 29189941), vortioxetine is known to act as a serotonin (5-HT) transporter (SERT) inhibitor combined with 5-HT3, 5-HT7, and 5-HT1D receptor antagonism, 5-HT1B partial agonism, and 5-HT1A agonism — a "multimodal" profile that increases serotonergic, noradrenergic, dopaminergic, and cholinergic neurotransmission. Its efficacy in MDD has been well established through multiple Phase 3 registration trials and network meta-analyses.

"Neurotic disorder" is a broad, now largely retired ICD-9 classification that encompasses anxiety, dissociative, and somatoform symptom clusters rather than a single well-defined disease entity. Since anxiety commonly co-occurs with depression, and vortioxetine's serotonergic multimodal mechanism has a theoretical rationale for anxiety-comorbid depression, the biological plausibility for this link is not unreasonable.

However, the model's own rationale flags an important caveat: current evidence for "neurotic disorder" is only indirect (a general-population real-world antidepressant cohort study and a case-report-style review focused on a narrower, related term — "neurotic depression") and does not specifically validate this broad diagnostic category. Notably, this same evidence pack contains two closely related, more specific candidate terms — melancholia and neurotic depression — each supported by Phase 3 RCT-level evidence (evidence level L1) and multiple network meta-analyses, including the well-known Cipriani et al. 21-antidepressant comparison (PMID 29477251). Those candidates represent substantially stronger, more actionable repurposing signals than the top-ranked "neurotic disorder" prediction evaluated here.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04446039	N/A	Completed	370,212	Real-world retrospective cohort using nationwide claims data comparing medication utilization patterns and adverse-outcome risk across commonly used antidepressants; population is general depression patients, not specifically defined as "neurotic disorder" — relevance graded C (indirect).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31006795	2019	Review (case report)	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova	Case report on "neurotic depression" treatment approaches, noting the benefit of combining antidepressants with cognitive behavioral therapy; addresses a narrower diagnosis than the broader "neurotic disorder" category.

Finland Market Information

Vortioxetine currently has no marketing authorization in Finland (0 licenses on record).

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data are not currently available in this evidence pack (TFDA/Fimea package insert review is flagged as a Blocking data gap, DG001).

Conclusion and Next Steps

Decision: Research Question

Rationale: The TxGNN score for "neurotic disorder" is high, but supporting evidence is limited to one indirect real-world cohort study and one review discussing a related but narrower diagnosis. No study directly evaluates vortioxetine in a population specifically diagnosed with the broad "neurotic disorder" category, so this remains a hypothesis-generating signal rather than an actionable repurposing case.

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism-of-action data from DrugBank — currently a High-severity data gap (DG002)
A study or trial specifically targeting the "neurotic disorder" diagnostic category (anxiety/dissociative/somatoform spectrum), rather than proxy terms like general antidepressant cohorts
Consider prioritizing the related, better-supported candidates in this same evidence pack — melancholia and neurotic depression — both rated L1 evidence with Phase 3 RCT support and recommended as "Proceed with Guardrails"
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.